<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Asparaginase" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Asparaginase</book-part-id>
      <title-group>
        <title>Asparaginase</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>9</month>
          <year>2023</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Ashwagandha" document-type="chapter">Ashwagandha</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Aspirin" document-type="chapter">Aspirin</related-object>
    </book-part-meta>
    <body>
      <sec id="Asparaginase.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Asparaginase.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Asparaginase is a bacterial enzyme that is used as an antineoplastic agent, largely in the therapy of acute lymphocytic leukemia (ALL). Asparaginase has many side effects, one of which is hepatic injury that is characterized by inhibition of hepatic protein synthesis, marked cholestasis and steatosis, which is usually reversible but can be severe and lead to death from hepatic failure.</p>
        </sec>
        <sec id="Asparaginase.Background">
          <title>Background</title>
          <p>Asparaginase (as par' a jin ase), often referred to as L-asparaginase, is a bacterial enzyme that acts to decrease tissue stores of asparagine, a secondary amino acid that is important in the growth of many cancers. Asparaginase, prepared from E. coli, was introduced into cancer chemotherapy over 50 years ago and remains an important agent in the therapy of acute lymphocytic leukemia. Asparaginase has activity against other cancer types but is rarely used for other indications. Asparaginase was first approved for use in the United States in 1972 as an anticancer agent, with initial preparations being prepared from E. coli. Pegylated formulations of E. coli-derived asparaginase (pegaspargase) became available and were approved for use in 1994 and are currently available under the brand name Oncaspar. Another form of pegylated asparaginase referred to as calaspargase pegol (brand name Asparlas) was approved in 2018 as therapy of ALL in children and young adults (ages 1 month to 21 years). These preparations can be given every two (pegaspargase) or three (calaspargase) weeks and have largely replaced standard asparaginase. Asparaginase made from other bacteria (Erwinia chrysanthemi) was approved for use in the United States in 2011 under the brand name Erwinaze, and a recombinant form was originally approved in 2021 under the brand name Rylaze. Standard asparaginase is given either by intramuscular injection or, more typically, intravenous injection in doses of 25,000 IU/m<sup>2</sup> three times weekly in 14-day cycles. Pegaspargase can also be given intramuscularly or intravenously, typically in a dose of 2500 IU/m<sup>2</sup> every two or three weeks. Both standard and pegylated asparaginase are usually given in combination with other antineoplastic agents such as vincristine, mercaptopurine, methotrexate, daunorubicin, and prednisone. Asparaginase has many dose related toxicities including nausea, fever, hypersensitivity reactions (urticaria, wheezing), clotting abnormalities, bone marrow suppression, pancreatitis, hepatotoxicity and central nervous system toxicities.</p>
        </sec>
        <sec id="Asparaginase.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Some abnormalities of liver test results occur in almost all patients treated with either asparaginase or pegaspargase. Most typical is a decrease in serum albumin and clotting factors (including II, V, VII, VIII, IX, prothrombin and fibrinogen) due to inhibition of hepatic protein synthesis. Most patients also have a rise in alkaline phosphatase levels and a lower proportion have increases in serum aminotransferase levels and bilirubin. Symptoms of fatigue and anorexia may be present. The inhibition of clotting factor and thrombolytic activity rarely results in excess bleeding, but paradoxically can also cause excessive clotting and a hypercoagulable state. Serum aminotransferase elevations during asparaginase therapy are mild-to-moderate in severity (2 to 10 times the upper limit of normal) and self-limiting. The abnormalities typically arise after 2 to 3 weeks of therapy and resolve within 2 to 4 weeks of stopping.</p>
          <p>Asparaginase and pegasparase can also result in a more severe and protracted form of liver injury marked by fatigue, dark urine and jaundice arising 2 to 3 weeks after starting the enzyme infusions and often between courses of therapy. The hepatic dysfunction is accompanied by hepatic steatosis which can be severe and accompanied by jaundice, hepatomegaly and evidence of hepatic failure (somnolence, coma, ascites). Imaging of the liver shows hepatomegaly and marked fat accumulation arising within a few weeks of starting the agent and sometimes after a single dose. Autoimmune and immunoallergic features are uncommon. The course of illness varies. Recovery tends to be slow, jaundice resolving in 2 to 8 weeks and serum enzymes thereafter. Deaths due to asparaginase hepatotoxicity have been reported but are rare (Case 1). The frequency of this clinically apparent liver injury after asparginase therapy is estimated to be 15% to 20% in adults but less than 5% in children. Furthermore, the rate of severe hepatic injury from asparaginase has been less frequent in recent years, perhaps due to safer dosage regimens, more purified preparations of the bacterial enzyme, better monitoring and dose adjustments based upon better understanding of pharmacokinetics. Nevertheless, the frequency of hepatotoxicity appears to be similar with standard and pegylated forms of asparaginase. Risk factors for clinically apparent liver injury include higher doses, older age and preexisting obesity, hyperlipidemia and diabetes. Although of unproven benefit, therapy with L-carnitine and vitamin B is often recommended. Interestingly, in many instances asparaginase therapy is tolerated after recovery from the acute episode with either no or milder liver injury (Case 2). Switching from an E. coli to an Erwinia chrysanthemi-derived asparaginase may also be less likely to induce a recurrence of hepatic injury.</p>
          <p>The clinical features of hepatic injury due to asparaginase can be overshadowed by its other systemic toxicities, including severe nausea and vomiting, weakness, edema, pancreatitis and encephalopathy. Although hypersensitivity reactions to asparaginase are common (it is a bacterial not a human enzyme), these usually occur early before the appearance of liver injury and the hepatic injury is rarely accompanied by fever or eosinophilia or autoantibody formation.</p>
          <p>Likelihood score: A (well known cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Asparaginase.Mechanism_of_Liver_Injury">
          <title>Mechanism of Liver Injury</title>
          <p>Asparaginase is directly toxic to hepatocytes resulting in inhibition of protein synthesis and export of lipoproteins and lipids, with resultant steatosis and hepatic dysfunction. As with other forms of direct hepatotoxicity, the liver injury attributed to asparaginase arises rapidly, is dose related, and is rarely accompanied by with immunological features. The mechanism of the direct injury is not clear but may be the result of substrate depletion of asparagine or possibly arginine (as a consequence of argininase activity in the bacterial enzyme preparation). In animal models, asparaginase causes similar hepatic injury to that in humans. Hepatic injury with Erwinia-derived asparaginase may be less common than with E. coli-derived enzyme, but head-to-head comparisons have not been made.</p>
        </sec>
        <sec id="Asparaginase.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>Asparaginase is typically given in 14 or 28 day cycles while pegaspargase is given at two-week intervals, and consequently the hepatic injury may first become clinically apparent after the drug is stopped. Further use of asparaginase (with dose reduction) should be delayed until hepatic function has been restored. Patients receiving asparaginase should be monitored for hepatic function and the drug stopped or dose adjusted if liver test abnormalities arise. Once clinically apparent liver injury arises, supportive clinical care and treatment of complications are essential. Anecdotal reports suggest that intravenous infusions of L-carnitine (50 mg/kg daily in divided doses for 5 to 8 days or until the injury resolves) and vitamin B preparations may be helpful. The efficacy of L-carnitine in ameliorating or preventing hepatic injury from asparaginase has not been shown in prospective controlled trials, but the approach appears to be safe and without serious adverse effects. In animal models, L-carnitine ameliorates the hepatic injury induced by asparaginase as do infusions of arginine.</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="AntineoplasticAgents" document-type="chapter">Antineoplastic Agents</related-object></p>
        </sec>
      </sec>
      <sec id="Asparaginase.CASE_REPORTS">
        <title>CASE REPORTS</title>
        <sec id="Asparaginase.Case_1_Severe_hepatic_injur">
          <title>Case 1. Severe hepatic injury and death due to asparaginase.(<xref ref-type="bibr" rid="Asparaginase.REF.1">1</xref>)</title>
          <p>A 68 year old man with acute lymphocytic leukemia was treated with induction chemotherapy using daunorubicin, vincristine, methotrexate, asparaginase, cyclophosphamide and prednisone. Mild liver test abnormalities were present even before therapy but rose precipitously between day 19 and 26 of therapy. Chemotherapy was stopped. Serum bilirubin was 10.9 mg/dL, ALT 122 U/L and alkaline phosphatase 480 U/L (Table). A liver biopsy showed diffuse microvesicular steatosis with minimal inflammation, necrosis or fibrosis. Several days later, he became progressively somnolent and was transferred to the intensive care unit. Serum ammonia levels were high (227 &#x000b5;mol/L; normal &#x0003c;35), but lactate and glucose levels were normal. He developed progressive coma, sepsis, renal failure and died 54 days after starting therapy and 4 weeks after stopping all chemotherapy.</p>
          <sec id="Asparaginase.Key_Points">
            <title>Key Points</title>
            <table-wrap id="Asparaginase.Tc" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <tbody>
                  <tr>
                    <th id="hd_b_Asparaginase.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Medication:</th>
                    <td headers="hd_b_Asparaginase.Tc_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">Asparaginase (dose not given)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Asparaginase.Tc_1_1_2_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pattern:</th>
                    <td headers="hd_b_Asparaginase.Tc_1_1_2_1" valign="top" align="left" rowspan="1" colspan="1">Cholestatic (R=0.7)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Asparaginase.Tc_1_1_3_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Severity:</th>
                    <td headers="hd_b_Asparaginase.Tc_1_1_3_1" valign="top" align="left" rowspan="1" colspan="1">5+ (jaundice, hepatic failure and death)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Asparaginase.Tc_1_1_4_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Latency:</th>
                    <td headers="hd_b_Asparaginase.Tc_1_1_4_1" valign="top" align="left" rowspan="1" colspan="1">26 days</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Asparaginase.Tc_1_1_5_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Recovery:</th>
                    <td headers="hd_b_Asparaginase.Tc_1_1_5_1" valign="top" align="left" rowspan="1" colspan="1">None</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Asparaginase.Tc_1_1_6_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Other medications:</th>
                    <td headers="hd_b_Asparaginase.Tc_1_1_6_1" valign="top" align="left" rowspan="1" colspan="1">Chemotherapy for leukemia included prednisone, daunorubicin, vincristine, methotrexate, and cyclophosphamide.</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Asparaginase.Laboratory_Values">
            <title>Laboratory Values</title>
            <table-wrap id="Asparaginase.Td" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_Asparaginase.Td_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">Time After<break/>Starting</th>
                    <th id="hd_h_Asparaginase.Td_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">Time After<break/>Stopping</th>
                    <th id="hd_h_Asparaginase.Td_1_1_1_3" valign="top" align="center" scope="col" rowspan="1" colspan="1">ALT<break/>(U/L)</th>
                    <th id="hd_h_Asparaginase.Td_1_1_1_4" valign="top" align="center" scope="col" rowspan="1" colspan="1">Alk P<break/>(U/L)</th>
                    <th id="hd_h_Asparaginase.Td_1_1_1_5" valign="top" align="center" scope="col" rowspan="1" colspan="1">Bilirubin<break/>(mg/dL)</th>
                    <th id="hd_h_Asparaginase.Td_1_1_1_6" valign="top" align="left" scope="col" rowspan="1" colspan="1">Other</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">pre</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">50</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">159</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">2.4</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Started chemotherapy</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">5 days</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">144</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">141</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.8</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">11 days</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">182</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">110</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">1.0</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">19 days</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">124</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">64</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">1.0</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">26 days</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">122</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">480</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">10.9</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Chemotherapy stopped</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">28 days</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">2 days</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">111</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">588</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">11.9</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Liver biopsy</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">32 days</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">6 days</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">132</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">982</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">19.5</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Somnolence</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">42 days</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">16 days</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">526</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">2735</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">20.9</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Coma</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">50 days</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">24 days</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">184</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">2688</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">32.0</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">54 days</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">28 days</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_3 hd_h_Asparaginase.Td_1_1_1_4 hd_h_Asparaginase.Td_1_1_1_5 hd_h_Asparaginase.Td_1_1_1_6" colspan="4" valign="top" align="left" rowspan="1">Died of hepatic and multiorgan failure</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_1 hd_h_Asparaginase.Td_1_1_1_2" colspan="2" valign="top" align="center" scope="row" rowspan="1">
<bold>Normal Values</bold>
</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;38</bold>
</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;107</bold>
</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;1.2</bold>
</td>
                    <td headers="hd_h_Asparaginase.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Asparaginase.Comment">
            <title>Comment</title>
            <p>While this patient was receiving 6 chemotherapeutic agents concurrently, the hepatic injury most closely resembled asparaginase hepatotoxicity, which typically arises after 2 to 3 weeks of therapy and is marked by gradual elevations in alkaline phosphatase to high levels with variable increases in serum bilirubin and aminotransferase levels. Some cases are severe and associated with hepatomegaly, fatty metamorphosis, severe hepatic dysfunction, progressive jaundice and hepatic coma. The condition can progress for several weeks after stopping therapy and rare fatal instances such as the current case have been described. Complicating factors in this case were age and possibly preexisting liver disease. Asparaginase toxicity is not idiosyncratic, but there appears to be variable susceptibility to the injury, and risk factors include dose, age, obesity and preexisting diabetes. Early in the course, the fatty metamorphosis may be largely microvesicular steatosis, whereas later, a mixed or fully macrovesicular steatosis may be present. Unlike the acute fatty liver with hepatic failure that occurs with Reye syndrome and mitochondrial injury due to nucleoside analogues, the steatosis and liver injury associated with asparaginase is less commonly associated with lactic acidosis, hyperammonemia and hypoglycemia, although it can be accompanied by pancreatitis. Unlike the fatty liver that occurs with alcoholic and nonalcoholic liver disease (NASH), there is little ballooning degeneration, Mallory bodies or sinusoidal fibrosis.</p>
          </sec>
        </sec>
        <sec id="Asparaginase.Case_2_Liver_injury_due_to">
          <title>Case 2. Liver injury due to pegaspargase with recurrence on re-exposure.(<xref ref-type="bibr" rid="Asparaginase.REF.2">2</xref>)</title>
          <p>A 33 year old woman with acute lymphocytic leukemia was treated with induction chemotherapy using daunorubicin, vincristine, methotrexate, cytarabine, prednisone, and pegaspargase. Routine liver tests were normal before starting chemotherapy. Pegaspargase was given as a single intravenous infusion of 2520 IU on day 4. She developed symptoms of fatigue, weakness, nausea, and poor appetite a week after the pegaspargase infusion. Her symptoms persisted, and two weeks later she noted dark urine and jaundice and was found to have abnormal liver tests. Serum bilirubin was 8.4 mg/dL, ALT 1076 U/L and alkaline phosphatase 314 U/L (Table). Serum albumin was 1.5 g/dL and INR 1.1. All chemotherapy was stopped, and she was hospitalized. An abdominal ultrasound showed changes suggestive of hepatic steatosis but no evidence of biliary obstruction or gall stones. Tests for hepatitis A, B and C were negative. She had low levels of ANA (1:80), but SMA and AMA were negative, and immunoglobulin levels were normal. She was monitored on no therapy. Liver tests began to improve, and chemotherapy was restarted. A single infusion of pegaspargase was given and a few weeks later she again developed fatigue and dark urine and liver tests rose: bilirubin from 0.8 to 3.8 mg/dL, ALT from 47 to 533 U/L, and Alk P from 194 to 1018 U/L. Chemotherapy was held and liver tests improved once again. In follow up, chemotherapy was restarted with addition of mercaptopurine instead of pegaspargase. Eight months later she was in remission and all liver tests were normal.</p>
          <sec id="Asparaginase.Key_Points_1">
            <title>Key Points</title>
            <table-wrap id="Asparaginase.Te" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <tbody>
                  <tr>
                    <th id="hd_b_Asparaginase.Te_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Medication:</th>
                    <td headers="hd_b_Asparaginase.Te_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">Pegaspargase</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Asparaginase.Te_1_1_2_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pattern:</th>
                    <td headers="hd_b_Asparaginase.Te_1_1_2_1" valign="top" align="left" rowspan="1" colspan="1">Hepatocellular (R=14.5)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Asparaginase.Te_1_1_3_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Severity:</th>
                    <td headers="hd_b_Asparaginase.Te_1_1_3_1" valign="top" align="left" rowspan="1" colspan="1">3+ (jaundice, hospitalization)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Asparaginase.Te_1_1_4_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Latency:</th>
                    <td headers="hd_b_Asparaginase.Te_1_1_4_1" valign="top" align="left" rowspan="1" colspan="1">21 days</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Asparaginase.Te_1_1_5_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Recovery:</th>
                    <td headers="hd_b_Asparaginase.Te_1_1_5_1" valign="top" align="left" rowspan="1" colspan="1">Recurrence with re-exposure, ultimate complete recovery 8 months later</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Asparaginase.Te_1_1_6_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Other medications:</th>
                    <td headers="hd_b_Asparaginase.Te_1_1_6_1" valign="top" align="left" rowspan="1" colspan="1">Chemotherapy for leukemia included prednisone, daunorubicin, vincristine, methotrexate, and cytarabine.</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Asparaginase.Laboratory_Values_1">
            <title>Laboratory Values</title>
            <table-wrap id="Asparaginase.Tf" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_Asparaginase.Tf_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">Time After<break/>Starting</th>
                    <th id="hd_h_Asparaginase.Tf_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">Time After<break/>Stopping</th>
                    <th id="hd_h_Asparaginase.Tf_1_1_1_3" valign="top" align="center" scope="col" rowspan="1" colspan="1">ALT<break/>(U/L)</th>
                    <th id="hd_h_Asparaginase.Tf_1_1_1_4" valign="top" align="center" scope="col" rowspan="1" colspan="1">Alk P<break/>(U/L)</th>
                    <th id="hd_h_Asparaginase.Tf_1_1_1_5" valign="top" align="center" scope="col" rowspan="1" colspan="1">Bilirubin<break/>(mg/dL)</th>
                    <th id="hd_h_Asparaginase.Tf_1_1_1_6" valign="top" align="left" scope="col" rowspan="1" colspan="1">Other</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">pre</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">46</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">76</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.6</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Started chemotherapy</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">4 days</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">-20 days</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Pegaspargase given iv</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">9 days</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">-14 days</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">66</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">70</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">1.7</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Onset of symptoms</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">23 days</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">1076</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">193</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">8.4</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Hospitalization</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">26 days</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">3 days</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">2331</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">314</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">12.8</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Ultrasound: steatosis</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">30 days</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">7 days</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">1112</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">420</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">3.0</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Discharged</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">5 weeks</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">13 days</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">217</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">218</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">2.3</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Chemotherapy restarted</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">16 days</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">200</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">183</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">1.5</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">7 weeks</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">4 weeks</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">57</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">126</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">1.3</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Pegaspargase given iv</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">2 months</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">5 weeks</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">47</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">193</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">1.2</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">6 weeks</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">67</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">194</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.8</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">7 weeks</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">533</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">1018</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">3.8</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Fatigue and dark urine</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">7.5 weeks</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">294</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">780</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">1.6</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">3 months</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">8 weeks</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">191</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">416</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.9</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">11 weeks</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">57</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">163</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.5</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Mercaptopurine started</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">4 months</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">3 months</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">76</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">133</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.7</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">4 months</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">56</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">119</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.3</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">9 months</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">8 months</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">37</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">92</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.6</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">In remission</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_1 hd_h_Asparaginase.Tf_1_1_1_2" colspan="2" valign="top" align="left" scope="row" rowspan="1">
<bold>Normal Values</bold>
</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;50</bold>
</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;125</bold>
</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;1.2</bold>
</td>
                    <td headers="hd_h_Asparaginase.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Asparaginase.Comment_1">
            <title>Comment</title>
            <p>This patient developed typical asparaginase hepatotoxicity starting within a week of starting chemotherapy and with peak levels of enzyme elevations and jaundice 3 weeks after the single infusion of pegaspargase. Also typical was the fall in serum protein levels and marked hepatic steatosis. A liver biopsy was not done but asparaginase hepatotoxicity was suspected. Once it was clear that she was recovering, chemotherapy was restarted, and she was given another infusion of pegaspargase. Two weeks later she was again symptomatic and jaundiced, this second episode being somewhat less severe than the first. Unlike with immunoallergic forms of idiopathic drug induced liver injury, rechallenge with asparaginase often causes a less severe recurrence and can be mild and subclinical. Because of the importance of asparaginase in treatment of acute leukemia, attempts are often made to restart the agent despite a severe episode of hepatotoxicity. Rechallenge with asparaginase should be done cautiously, perhaps with a lower dose or a different formulation (such as Erwinia chrysanthemi derived asparaginase).</p>
          </sec>
        </sec>
      </sec>
      <sec id="Asparaginase.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
<bold>REPRESENTATIVE TRADE NAMES</bold>
</p>
        <p>Asparaginase &#x02013; Erwinaze&#x000ae;</p>
        <p>Asparaginase (recombinant) &#x02013; Rylaze&#x000ae;</p>
        <p>Pegaspargase &#x02013; Oncaspar&#x000ae;</p>
        <p>
<bold>DRUG CLASS</bold>
</p>
        <p>Antineoplastic Agents</p>
        <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Asparaginase">COMPLETE LABELING</ext-link> [Asparaginase]</p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Asparaginase.CHEMICAL_FORMULAS_AND_STRUC">
        <title>CHEMICAL FORMULAS AND STRUCTURES</title>
        <table-wrap id="Asparaginase.Tg" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Asparaginase.Tg_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Asparaginase.Tg_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_h_Asparaginase.Tg_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Asparaginase.Tg_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Asparaginase.Tg_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Asparaginase</td>
                <td headers="hd_h_Asparaginase.Tg_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/substance/135362876">9015-68-3</ext-link>
</td>
                <td headers="hd_h_Asparaginase.Tg_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">Large protein</td>
                <td headers="hd_h_Asparaginase.Tg_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">Unavailable</td>
              </tr>
              <tr>
                <td headers="hd_h_Asparaginase.Tg_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pegaspargase</td>
                <td headers="hd_h_Asparaginase.Tg_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/substance/135352519">130167-69-0</ext-link>
</td>
                <td headers="hd_h_Asparaginase.Tg_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">Large protein</td>
                <td headers="hd_h_Asparaginase.Tg_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">Unavailable</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Asparaginase.CITED_REFERENCES">
        <title>CITED REFERENCES</title>
        <ref-list id="Asparaginase.CITED_REFERENCES.reflist0">
          <ref id="Asparaginase.REF.1">
            <label>1</label>
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bodmer</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sulz</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stadlmann</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Droll</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Terracciano</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kr&#x000e4;henb&#x000fc;hl</surname>
<given-names>S</given-names></string-name>. <article-title>Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase.</article-title>
<source>Digestion</source>
<year>2006</year>; <volume>74</volume>: <fpage>28</fpage>-<lpage>32</lpage>.<pub-id pub-id-type="pmid">16988508</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.2">
            <label>2</label>
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kamal</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Koh</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Samala</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Fontana</surname>
<given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Stolz</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Durazo</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hayashi</surname>
<given-names>PH</given-names></string-name>, <etal>et al.</etal>; <collab>Drug-Induced Liver Injury Network</collab>. <article-title>Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis.</article-title>
<source>Hepatol Int.</source>
<year>2019</year>;<volume>13</volume>:<fpage>641</fpage>-<lpage>648</lpage>. <comment>[Case #6]</comment><pub-id pub-id-type="pmid">31392570</pub-id></mixed-citation>
          </ref>
        </ref-list>
      </sec>
      <sec id="Asparaginase.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 20 July 2023</p>
        <p>Abbreviations: ALL, acute lymphocytic leukemia.</p>
        <ref-list id="Asparaginase.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Asparaginase.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Hepatotoxic effects of oncotherapeutic and immunosuppressive agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 673-708.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity of neoplastic agents published in 1999; mentions high incidence of hepatic and pancreatic side effects from asparaginase, liver injury marked by steatosis which is found in 50-90% of patients and worsens with duration of treatment).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.deleve.2013">
            <mixed-citation publication-type="book">DeLeve L. L-asparaginase. Cancer chemotherapy. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 557.<annotation><p><italic toggle="yes">(Review of hepatotoxicity of anticancer drugs states that the rate of liver test abnormalities and clinically apparent liver injury due to asparaginase therapy is considerably lower in the recent literature, although severe cases are still reported).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.chabner.2011">
            <mixed-citation publication-type="book">Chabner BA, Bertino J, Clearly J, Ortiz T, Lane A, Supko JG, Ryan DP. Cytotoxic agents. Chemotherapy of neoplastic diseases. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1677-730.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics; mentions that the toxicity of asparaginase is due to its antigenicity and to its actions in inhibiting protein synthesis).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.haskell.1969.1028">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Haskell</surname>
<given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Canellos</surname>
<given-names>GP</given-names></string-name>, <string-name name-style="western"><surname>Leventhal</surname>
<given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Carbone</surname>
<given-names>PP</given-names></string-name>, <string-name name-style="western"><surname>Block</surname>
<given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Serpick</surname>
<given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Selawry</surname>
<given-names>OS</given-names></string-name>. <article-title>L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease.</article-title>
<source>N Engl J Med</source>
<year>1969</year>; <volume>281</volume>: <fpage>1028</fpage>-<lpage>34</lpage>.<annotation><p><italic toggle="yes">(Early experience with asparaginase in 55 patients with cancer or leukemia, given iv for 3 weeks; common side effects were nausea, fever, hypersensitivity reactions, clotting abnormalities, pancreatitis and CNS toxicity; the most frequent side effect was liver dysfunction characterized by decreases in serum albumin and slight elevations in Alk P, ALT and bilirubin; in one instance liver injury was severe).</italic></p></annotation><pub-id pub-id-type="pmid">4898857</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.gross.1969.733">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gross</surname>
<given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Speer</surname>
<given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Hill</surname>
<given-names>JM</given-names></string-name>. <article-title>Hepatic lipidosis associated with L-asparaginase treatment.</article-title>
<source>Proc Soc Exp Biol Med</source>
<year>1969</year>; <volume>130</volume>: <fpage>733</fpage>-<lpage>6</lpage>.<annotation><p><italic toggle="yes">(Study in mice given different doses of asparaginase with different degrees of purity; highest purity samples had little hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">5773660</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.pratt.1970.474">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Pratt</surname>
<given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Simone</surname>
<given-names>JV</given-names></string-name>, <string-name name-style="western"><surname>Zee</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Aur</surname>
<given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname>
<given-names>WW</given-names></string-name>. <article-title>Comparison of daily versus weekly L-asparaginase for the treatment of childhood acute leukemia.</article-title>
<source>J Pediatr</source>
<year>1970</year>; <volume>77</volume>: <fpage>474</fpage>-<lpage>83</lpage>.<annotation><p><italic toggle="yes">(Comparison of daily versus weekly infusions of asparaginase in 19 children with acute leukemia; evidence of hepatotoxicity occurred in all patients with decrease in albumin in 68%, increase in AST in 63%, Alk P in 16%, bilirubin in 47%, liver changes found on autopsies were "vacuolization of hepatocytes").</italic></p></annotation><pub-id pub-id-type="pmid">5278225</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.leventhal.1970.47">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Leventhal</surname>
<given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Skeel</surname>
<given-names>RT</given-names></string-name>, <string-name name-style="western"><surname>Yankee</surname>
<given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Henderson</surname>
<given-names>ES</given-names></string-name>. <article-title>L-asparaginase (NSC- 09229) plus azaserine (NSC-742) in acute lymphatic leukemia.</article-title>
<source>Cancer Chemother Rep</source>
<year>1970</year>; <volume>54</volume>: <fpage>47</fpage>-<lpage>51</lpage>.<annotation><p><italic toggle="yes">(Result of use of asparaginase and azaserine in 27 children with acute lymphocytic leukemia; hypersensitivity reactions occurred in 33%, Alk P elevations in 77%, decreases in albumin in 59%, clotting abnormalities in 88%).</italic></p></annotation><pub-id pub-id-type="pmid">4945997</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.oettgen.1970.253">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Oettgen</surname>
<given-names>HF</given-names></string-name>, <string-name name-style="western"><surname>Stephenson</surname>
<given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Schwartz</surname>
<given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Leeper</surname>
<given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Tallai</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname>
<given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Clarkson</surname>
<given-names>BD</given-names></string-name>, <etal>et al.</etal>
<article-title>Toxicity of E. coli L-asparaginase in man.</article-title>
<source>Cancer</source>
<year>1970</year>; <volume>25</volume>: <fpage>253</fpage>-<lpage>78</lpage>.<annotation><p><italic toggle="yes">(Analysis of toxicity of asparaginase in 131 children and 143 adults with neoplastic disease; elevations in Alk P occurred in 31-47% of patients, AST in 46-63%, bilirubin in 29-51%, and decreases in albumin in 71-82%, usually arising during the 2nd to 3rd week of therapy and resolving upon stopping; fatty metamorphosis found in 73% of autopsies).</italic></p></annotation><pub-id pub-id-type="pmid">4905153</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.bernard.1970.161">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bernard</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jacquillat</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Boiron</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Weil</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bussel</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Larrieu</surname>
<given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Delobel</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal>
<comment>[Treatment of acute leukemia with the L-asparaginase. Preliminary results based on 84 cases]</comment>. <source>Presse Med.</source>
<year>1970</year>; <volume>78</volume>: <fpage>161</fpage>-<lpage>6</lpage>. <comment>French.</comment><annotation><p><italic toggle="yes">(Analysis of results of treating 75 patients with acute leukemia with asparaginase; liver toxicity was frequent and marked by falls in serum albumin and cholesterol with rises in Alk P, while ALT elevations were rare; two patients developed hepatic insufficiency which may have contributed to their deaths).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.burchenal.1970.350">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Burchenal</surname>
<given-names>JH</given-names></string-name>. <article-title>A summary of the clinical status of asparaginase.</article-title>
<source>Recent Results Cancer Res</source>
<year>1970</year>; <volume>33</volume>: <fpage>350</fpage>-<lpage>4</lpage>.<annotation><p><italic toggle="yes">(Summary of a workshop on asparaginase).</italic></p></annotation><pub-id pub-id-type="pmid">5292724</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.jacquillat.1970.263">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Jacquillat</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Weil</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bussel</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Loisel</surname>
<given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Rouesse</surname>
<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Larrieu</surname>
<given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Boiron</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>Treatment of acute leukemia with L-asparaginase--preliminary results on 84 cases.</article-title>
<source>Recent Results Cancer Res</source>
<year>1970</year>; <volume>33</volume>: <fpage>263</fpage>-<lpage>78</lpage>.<annotation><p><italic toggle="yes">(Among 84 patients with acute leukemia given asparaginase, early toxicities included hypersensitivity reactions [fever, urticaria and anaphylaxis], and late toxicities where often hepatic with weight loss and elevations in bilirubin, Alk P [50%] and ALT [36%], with decrease in albumin [60%], cholesterol [72%] and fibrinogen, usually arising after the first week of therapy and beginning to resolve within a week of stopping).</italic></p></annotation><pub-id pub-id-type="pmid">5292720</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.marmont.1970.296">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Marmont</surname>
<given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Damasio</surname>
<given-names>EE</given-names></string-name>. <article-title>Some clinical observations on the treatment with L-asparaginase of the acute leukemias.</article-title>
<source>Recent Results Cancer Res</source>
<year>1970</year>; <volume>33</volume>: <fpage>296</fpage>-<lpage>315</lpage>.<annotation><p><italic toggle="yes">(Discussion of side effects of asparaginase: "there can be no doubt that L-ase profoundly affects the liver cell").</italic></p></annotation><pub-id pub-id-type="pmid">4949165</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.carbone.1970.236">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Carbone</surname>
<given-names>PP</given-names></string-name>, <string-name name-style="western"><surname>Haskell</surname>
<given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Leventhal</surname>
<given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Block</surname>
<given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Selawry</surname>
<given-names>OS</given-names></string-name>. <article-title>Clinical experience with L-asparaginase.</article-title>
<source>Recent Results Cancer Res</source>
<year>1970</year>; <volume>33</volume>: <fpage>236</fpage>-<lpage>43</lpage>.<annotation><p><italic toggle="yes">(Summary of results using asparaginase, similar to report by Haskell [1969]).</italic></p></annotation><pub-id pub-id-type="pmid">4949163</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.zubrod.1970.555">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zubrod</surname>
<given-names>CG</given-names></string-name>. <article-title>The clinical toxicities of L-asparaginase in treatment of leukemia and lymphoma.</article-title>
<source>Pediatrics</source>
<year>1970</year>; <volume>45</volume>: <fpage>555</fpage>-<lpage>9</lpage>.<annotation><p><italic toggle="yes">(Review of toxicities of asparaginase, hepatic abnormalities being the most common).</italic></p></annotation><pub-id pub-id-type="pmid">5438160</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.beard.1970.191">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Beard</surname>
<given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Crowther</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Galton</surname>
<given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Guyer</surname>
<given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Fairley</surname>
<given-names>GH</given-names></string-name>, <string-name name-style="western"><surname>Kay</surname>
<given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Knapton</surname>
<given-names>PJ</given-names></string-name>, <etal>et al.</etal>
<article-title>L-asparaginase in treatment of acute leukaemia and lymphosarcoma.</article-title>
<source>Br Med J</source>
<year>1970</year>; <volume>1</volume> (<issue>5690</issue>): <fpage>191</fpage>-<lpage>5</lpage>.<annotation><p><italic toggle="yes">(Among 40 patients treated with L-asparaginase, nausea and vomiting were common as were "slight abnormalities in liver function tests").</italic></p></annotation><pub-id pub-id-type="pmid">4904933</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.pratt.1971.361">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Pratt</surname>
<given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname>
<given-names>WW</given-names></string-name>. <article-title>Duration and severity of fatty metamorphosis of the liver following L-asparaginase therapy.</article-title>
<source>Cancer</source>
<year>1971</year>; <volume>28</volume>: <fpage>361</fpage>-<lpage>4</lpage>.<annotation><p><italic toggle="yes">(Analysis of liver histology from autopsies in 31 children after asparaginase therapy, 27 [87%] had fatty metamorphosis for periods of up to 261 days after last dose, severity decreasing 60 days after dosing, but fatty change also found in 51% of children with leukemia who did not receive asparaginase).</italic></p></annotation><pub-id pub-id-type="pmid">5109448</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.biggs.1971.1">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Biggs</surname>
<given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Chesterman</surname>
<given-names>CN</given-names></string-name>, <string-name name-style="western"><surname>Holliday</surname>
<given-names>J</given-names></string-name>. <article-title>L-asparaginase--clinical experience in leukaemia, lymphoma and carcinoma.</article-title>
<source>Aust N Z J Med</source>
<year>1971</year>; <volume>1</volume>: <fpage>1</fpage>-<lpage>7</lpage>.<annotation><p><italic toggle="yes">(Among 11 patients with leukemia or cancer treated with asparaginase, mild elevations in ALT and Alk P [2-4 times ULN] occurred in 4).</italic></p></annotation><pub-id pub-id-type="pmid">4934741</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.revol.1971.831">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Revol</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Fi&#x000e8;re</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Guyon</surname>
<given-names>JM</given-names></string-name>. <comment>[Accidents due to asparaginase]</comment>. <source>J Med Lyon</source>
<year>1971</year>; <volume>52</volume>: <fpage>831</fpage>-<lpage>3</lpage>. <comment>French.</comment><pub-id pub-id-type="pmid">5136251</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.oberling.1971.1421">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Oberling</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Cazenave</surname>
<given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Lang</surname>
<given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Kurtz</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mayer</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Waitz</surname>
<given-names>R</given-names></string-name>. <comment>[Apropos of certain toxic effects of L-asparaginase in human therapy]</comment>. <source>Sem Hop</source>
<year>1971</year>; <volume>47</volume>: <fpage>1421</fpage>-<lpage>5</lpage>. <comment>French.</comment><pub-id pub-id-type="pmid">4326093</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.land.1972.339">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Land</surname>
<given-names>VJ</given-names></string-name>, <string-name name-style="western"><surname>Sutow</surname>
<given-names>WW</given-names></string-name>, <string-name name-style="western"><surname>Fernbach</surname>
<given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Lane</surname>
<given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname>
<given-names>TE</given-names></string-name>. <article-title>Toxicity of L-asparginase in children with advanced leukemia.</article-title>
<source>Cancer</source>
<year>1972</year>; <volume>30</volume>: <fpage>339</fpage>-<lpage>47</lpage>.<annotation><p><italic toggle="yes">(Among 105 patients with leukemia treated with asparaginase, liver test abnormalities occurred in most patients and were fatal in two [fatty liver]).</italic></p></annotation><pub-id pub-id-type="pmid">4626307</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.hasegawa.1973.917">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hasegawa</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Suzuki</surname>
<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Motegi</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Takanashi</surname>
<given-names>R.</given-names></string-name>
<comment>[Severe toxicity of L-asparaginase in the treatment of acute leukemia--the hepatocerebral lesions (author's transl)]</comment>. <source>Rinsho Ketsueki</source>
<year>1973</year>; <volume>14</volume>: <fpage>917</fpage>-<lpage>24</lpage>. <comment>Japanese.</comment><pub-id pub-id-type="pmid">4519904</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.haghbin.1974.1491">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Haghbin</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname>
<given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Clarkson</surname>
<given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Mik&#x000e9;</surname>
<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Burchenal</surname>
<given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Murphy</surname>
<given-names>ML</given-names></string-name>. <article-title>Intensive chemotherapy in children with acute lymphoblastic leukemia (L-2 protocol).</article-title>
<source>Cancer</source>
<year>1974</year>; <volume>33</volume>: <fpage>1491</fpage>-<lpage>8</lpage>.<annotation><p><italic toggle="yes">(Experience in treating 75 children with leukemia with intensive chemotherapy including asparaginase; two died of serum hepatitis from platelet transfusions; hepatotoxicity not discussed).</italic></p></annotation><pub-id pub-id-type="pmid">4526012</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.rutter.1975.1293">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Rutter</surname>
<given-names>DA</given-names></string-name>. <article-title>Letter: Toxicity of asparaginases.</article-title>
<source>Lancet</source>
<year>1975</year>; <volume>1</volume> (<issue>7919</issue>): <fpage>1293</fpage>-<lpage>4</lpage>.<annotation><p><italic toggle="yes">(Retrospective review of 77 courses of either E. coli or Erwinia carotovora derived asparaginase in patients with acute leukemia seen at 3 London hospitals, found slightly higher rates of side effects with E. coli product [liver injury not mentioned]; 10 patients with hypersensitivity reactions to one tolerated the other).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.olive.1976.259">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Olive</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Cartault</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Legras</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Neimann</surname>
<given-names>N.</given-names></string-name>
<comment>[Evaluation in children of the clinical, biological and electroencephalographic side effects of L-asparaginase]</comment>. <source>Pediatrie</source>
<year>1976</year>; <volume>31</volume>: <fpage>259</fpage>-<lpage>78</lpage>. <comment>French.</comment><pub-id pub-id-type="pmid">1069234</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.woods.1981.642">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Woods</surname>
<given-names>WG</given-names></string-name>, <string-name name-style="western"><surname>O'Leary</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nesbit</surname>
<given-names>ME</given-names></string-name>. <article-title>Life-threatening neuropathy and hepatotoxicity in infants during induction therapy for acute lymphoblastic leukemia.</article-title>
<source>J Pediatr</source>
<year>1981</year>; <volume>98</volume>: <fpage>642</fpage>-<lpage>5</lpage>.<annotation><p><italic toggle="yes">(Two children [ages 16 and 14 months] developed neuropathy and hepatic failure during 4th week of chemotherapy with regimens including asparaginase for acute lymphocytic leukemia, with liver biopsies showing fat, focal necrosis and mild inflammation, one survived and one died of hepatic failure).</italic></p></annotation><pub-id pub-id-type="pmid">6937637</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.haskell.1981.57">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Haskell</surname>
<given-names>CM</given-names></string-name>. <article-title>L-Asparaginase: human toxicology and single agent activity in nonleukemic neoplasms.</article-title>
<source>Cancer Treat Rep</source>
<year>1981</year>; <volume>65</volume>
<supplement>Suppl 4</supplement>: <fpage>57</fpage>-<lpage>9</lpage>.<annotation><p><italic toggle="yes">(Unlike other antineoplastic agents, asparaginase has little bone marrow toxicity and its main side effects are on liver, kidneys, pancreas, central nervous and clotting system; hypersensitivity reactions can also occur and can be severe).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.cairo.1982.335">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cairo</surname>
<given-names>MS</given-names></string-name>. <article-title>Adverse reactions of L-asparaginase.</article-title>
<source>Am J Pediatr Hematol Oncol</source>
<year>1982</year>
<season>Fall</season>; <volume>4</volume>: <fpage>335</fpage>-<lpage>9</lpage>.<annotation><p><italic toggle="yes">(Review of toxicity of asparaginase; hepatic injury is most common and is marked by changes in AST, Alk P, bilirubin and albumin).</italic></p></annotation><pub-id pub-id-type="pmid">6959544</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.distasio.1982.343">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Distasio</surname>
<given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Salazar</surname>
<given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Nadji</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Durden</surname>
<given-names>DL</given-names></string-name>. <article-title>Glutaminase-free asparaginase from vibrio succinogenes: an antilymphoma enzyme lacking hepatotoxicity.</article-title>
<source>Int J Cancer</source>
<year>1982</year>; <volume>30</volume>: <fpage>343</fpage>-<lpage>7</lpage>.<annotation><p><italic toggle="yes">(Unlike standard, E coli-derived asparaginase, a glutaminase-free preparation did not cause hepatotoxicity or fatty liver in mice, suggesting that the hepatotoxicity of asparaginase is due to a contaminant).</italic></p></annotation><pub-id pub-id-type="pmid">6752048</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.durden.1983.1602">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Durden</surname>
<given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Salazar</surname>
<given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Distasio</surname>
<given-names>JA</given-names></string-name>. <article-title>Kinetic analysis of hepatotoxicity associated with antineoplastic asparaginases.</article-title>
<source>Cancer Res</source>
<year>1983</year>; <volume>43</volume>: <fpage>1602</fpage>-<lpage>5</lpage>.<annotation><p><italic toggle="yes">(Comparison of glutaminase-free and standard asparaginase in a mouse model found little hepatotoxicity, even with 3-4 weeks of therapy).</italic></p></annotation><pub-id pub-id-type="pmid">6339039</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.kafkewitz.1983.1025">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kafkewitz</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bendich</surname>
<given-names>A</given-names></string-name>. <article-title>Enzyme-induced asparagine and glutamine depletion and immune system function.</article-title>
<source>Am J Clin Nutr</source>
<year>1983</year>; <volume>37</volume>: <fpage>1025</fpage>-<lpage>30</lpage>.<annotation><p><italic toggle="yes">(Induced immune deficiency in mice given E. coli derived asparaginase was associated with decrease in glutamine, which did not occur with V. succinogenes derived product that is free of glutaminase).</italic></p></annotation><pub-id pub-id-type="pmid">6342356</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.jenkins.1987">
            <mixed-citation publication-type="other">Jenkins R, Perlin E. Severe hepatotoxicity from Escherichia coli L-asparaginase. J Natl Med Assoc 1987; 79: 775, 779.<annotation><p><italic toggle="yes">(51 year old woman with diabetes and acute lymphocytic leukemia developed jaundice at the end of a 10 day course of asparaginase [bilirubin 9.0 rising to 25.5 mg/dL, AST 344 to 1920 U/L, Alk P 400 to 1650 U/L, with high ammonia and decreased fibrinogen], but gradually improved and all tests were normal 4 months later).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.bessho.1994.111">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bessho</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Kinumaki</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yokota</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hayashi</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kobayashi</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kamoshita</surname>
<given-names>S</given-names></string-name>. <article-title>Liver function studies in children with acute lymphocytic leukemia after cessation of therapy.</article-title>
<source>Med Pediatr Oncol</source>
<year>1994</year>; <volume>23</volume>: <fpage>111</fpage>-<lpage>5</lpage>.<annotation><p><italic toggle="yes">(Among 27 children with acute leukemia, serum ALT levels were often elevated during induction and maintenance therapy but were normal or near normal in all 3 months after stopping therapy and remained normal in long term follow up).</italic></p></annotation><pub-id pub-id-type="pmid">8202032</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.wr_bel.2000.67">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wr&#x000f3;bel</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Dobaczewski</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kazanowska</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Boguslawska-Jaworska</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Balwierz</surname>
<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Balcerska</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bubala</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal>
<comment>[Adverse reactions associated with the use of L-asparaginase during therapy of patients with B non-Hodgkin's lymphoma. Report of the Polish Paediatric Leukaemia/Lymphoma Study Group]</comment>. <source>Med Wieku Rozwoj</source>
<year>2000</year>; <volume>4</volume>: <fpage>67</fpage>-<lpage>72</lpage>. <comment>Polish.</comment><annotation><p><italic toggle="yes">(Abstract: among 66 children with non- Hodgkin lymphoma treated with asparaginase, 20 [30%] developed adverse reactions, mostly typically coagulation abnormalities [18%] and "impairment of liver function" [9%]).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.sahoo.2003.295">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sahoo</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hart</surname>
<given-names>J.</given-names></string-name>
<article-title>Histopathological features of L-asparaginase-induced liver disease.</article-title>
<source>Semin Liver Dis</source>
<year>2003</year>; <volume>23</volume>: <fpage>295</fpage>-<lpage>9</lpage>.<annotation><p><italic toggle="yes">(Four patients developed hepatomegaly and abnormal liver tests 2-20 days after starting asparaginase [bilirubin 1.6-39.0 mg/dL, ALT 69-3916 U/L, Alk P 118-1075 U/L, albumin 2.2-2.6 g/dL] and had diffuse macro- and micro-vesicular steatosis on liver biopsy; one patient had acute liver failure and died).</italic></p></annotation><pub-id pub-id-type="pmid">14523682</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.graham.2003.1293">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Graham</surname>
<given-names>ML</given-names></string-name>. <article-title>Pegaspargase: a review of clinical studies.</article-title>
<source>Adv Drug Deliv Rev</source>
<year>2003</year>; <volume>55</volume>: <fpage>1293</fpage>-<lpage>302</lpage>.<annotation><p><italic toggle="yes">(Review of clinical trials of pegylated asparaginase; toxicities were similar to the standard product and included hypoalbuminemia, lipoprotein abnormalities and elevations in ALT, Alk P and bilirubin).</italic></p></annotation><pub-id pub-id-type="pmid">14499708</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.bodmer.2006.28">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bodmer</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sulz</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stadlmann</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Droll</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Terracciano</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kr&#x000e4;henb&#x000fc;hl</surname>
<given-names>S</given-names></string-name>. <article-title>Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase.</article-title>
<source>Digestion</source>
<year>2006</year>; <volume>74</volume>: <fpage>28</fpage>-<lpage>32</lpage>.<annotation><p><italic toggle="yes">(68 year old man developed jaundice after 26 days of chemotherapy which included asparaginase [bilirubin 10.9 rising to 32.2 mg/dL, ALT 122 rising to 526 U/L, Alk P 480 rising to 2688 U/L], with progressive somnolence, hyperammonemia, coagulopathy, coma and death from liver failure 4 weeks later: Case 1).</italic></p></annotation><pub-id pub-id-type="pmid">16988508</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.florescalder_n.2009.790">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Flores-Calder&#x000f3;n</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Exiga-Gonzal&#x000e9;z</surname>
<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mor&#x000e1;n-Villota</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mart&#x000ed;n-Trejo</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yamamoto-Nagano</surname>
<given-names>A</given-names></string-name>. <article-title>Acute pancreatitis in children with acute lymphoblastic leukemia treated with L-asparaginase.</article-title>
<source>J Pediatr Hematol Oncol</source>
<year>2009</year>; <volume>31</volume>: <fpage>790</fpage>-<lpage>3</lpage>.<annotation><p><italic toggle="yes">(Among 266 children given chemotherapy [including asparaginase with prednisone, vincristine, daunorubicin and methotrexate] for acute lymphocytic leukemia over a 6 year period, 18 [7%] developed pancreatitis arising 1-18 days after last dose of asparaginase [amylase 19-2893 U/L]; no fatalities, but 3 developed a pseudocyst and chronic symptoms and 3 required long term insulin).</italic></p></annotation><pub-id pub-id-type="pmid">19770681</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.yong.2009.647">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yong</surname>
<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname>
<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname>
<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname>
<given-names>N</given-names></string-name>, <etal>et al.</etal>
<article-title>L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type.</article-title>
<source>Ann Hematol</source>
<year>2009</year>; <volume>88</volume>: <fpage>647</fpage>-<lpage>52</lpage>.<annotation><p><italic toggle="yes">(Among 45 adult patients receiving asparaginase for refractory and relapsed NKT cell leukemia, side effects included elevations in ALT in 51%, bilirubin in 33% and decreases in albumin in 9%).</italic></p></annotation><pub-id pub-id-type="pmid">19107482</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.ladas.2010.506">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ladas</surname>
<given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Kroll</surname>
<given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Oberlies</surname>
<given-names>NH</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ndao</surname>
<given-names>DH</given-names></string-name>, <string-name name-style="western"><surname>Rheingold</surname>
<given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Kelly</surname>
<given-names>KM</given-names></string-name>. <article-title>A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL).</article-title>
<source>Cancer</source>
<year>2010</year>; <volume>116</volume>: <fpage>506</fpage>-<lpage>13</lpage>.<annotation><p><italic toggle="yes">(Among 50 children with acute leukemia given maintenance chemotherapy [vincristine, mercaptopurine, methotrexate and prednisone] who had ALT elevations and who were treated with either milk thistle or placebo, there were few differences in subsequent ALT, AST and bilirubin levels, and elevations of serum ALT or AST above 5 times ULN occurred equally with or without milk thistle).</italic></p></annotation><pub-id pub-id-type="pmid">20014183</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.raetz.2010.554">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Raetz</surname>
<given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Salzer</surname>
<given-names>WL</given-names></string-name>. <article-title>Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia.</article-title>
<source>J Pediatr Hematol Oncol</source>
<year>2010</year>; <volume>32</volume>: <fpage>554</fpage>-<lpage>63</lpage>.<annotation><p><italic toggle="yes">(Review of safety and efficacy of asparaginase in children with ALL discusses hypersensitivity reactions and toxicity caused by inhibition of protein synthesis, which includes pancreatitis, thrombosis, and liver dysfunction, some degree of which occurs in most patients, with hepatic steatosis in 87% which often persists for months after discontinuation).</italic></p></annotation><pub-id pub-id-type="pmid">20724951</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.tsutsui.2012.531">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Tsutsui</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Koike</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Komatsu</surname>
<given-names>N.</given-names></string-name>
<comment>[Fulminant hepatitis possibly caused by L-asparaginase during induction chemotherapy in a patient with acute lymphoblastic leukemia]</comment>. <source>Rinsho Ketsueki.</source>
<year>2012</year>; <volume>53</volume>: <fpage>531</fpage>-<lpage>4</lpage>. <comment>Japanese.</comment><annotation><p><italic toggle="yes">(44 year old man with ALL developed abnormal liver tests 10 days after starting asparaginase with progressive injury and death by day 32).</italic></p></annotation><pub-id pub-id-type="pmid">22728556</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.okamura.2013.6">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Okamura</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nishimura</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sanada</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yakushijin</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Matsuoka</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yamamoto</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Minami</surname>
<given-names>H.</given-names></string-name>
<article-title>L-Asparaginase-induced fulminating liver dysfunction.</article-title>
<source>Int J Hematol</source>
<year>2013</year>; <volume>98</volume>: <fpage>6</fpage>-<lpage>7</lpage>.<annotation><p><italic toggle="yes">(49 year old woman with ALL developed liver test abnormalities 20 days after starting therapy with CHOP and 5 doses of asparaginase [bilirubin 2.2 mg/dL, ALT 43 U/L, Alk P not given], with hepatomegaly and marked fatty liver by CT scan; recovery by day 100).</italic></p></annotation><pub-id pub-id-type="pmid">23702916</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.roesmann.2013.167">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Roesmann</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Afify</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Panse</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Eisert</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Steitz</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tolba</surname>
<given-names>RH</given-names></string-name>. <article-title>L-carnitine ameliorates L-asparaginase-induced acute liver toxicity in steatotic rat livers.</article-title>
<source>Chemotherapy</source>
<year>2013</year>; <volume>59</volume>: <fpage>167</fpage>-<lpage>75</lpage>.<annotation><p><italic toggle="yes">(Pretreatment with L-carnitine decreased the liver injury and steatosis of isolated perfused rat livers exposed to asparaginase).</italic></p></annotation><pub-id pub-id-type="pmid">24192517</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.vetro.2014.271">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Vetro</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Giulietti</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Calafiore</surname>
<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Romano</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Di Raimondo</surname>
<given-names>F.</given-names></string-name>
<article-title>A snapshot of asparaginase-induced liver insufficiency.</article-title>
<source>Eur J Haematol</source>
<year>2014</year>; <volume>92</volume>: <fpage>271</fpage>-<lpage>2</lpage>.<annotation><p><italic toggle="yes">(39 year old man with ALL and renal transplant developed hepatomegaly and marked fatty liver [by CT scan] 25 days after starting pegaspargase [bilirubin not given; AST 90 U/L, Alk P 167 U/L, albumin 2.3 g/dL, fibrinogen 0, antithrombin III 19%], with progressive liver failure and death).</italic></p></annotation><pub-id pub-id-type="pmid">24329712</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.alnawakil.2014.1670">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Al-Nawakil</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Willems</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mauprivez</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Laffy</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Benm'rad</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tamburini</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fontaine</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal>
<article-title>Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors.</article-title>
<source>Leuk Lymphoma</source>
<year>2014</year>; <volume>55</volume>: <fpage>1670</fpage>-<lpage>4</lpage>.<annotation><p><italic toggle="yes">(Three patients, ages 51 to 64 years, developed severe liver injury 11-22 days after starting asparaginase therapy for ALL [peak bilirubin 6.1-50.4 mg/dL, ALT 480-1150 U/L, Alk P 550-2400 U/L, CT scan showing hepatomegaly and fatty liver], all 3 recovering after L-carnitine and vitamin B therapy).</italic></p></annotation><pub-id pub-id-type="pmid">24090500</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.saison.2014.13">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Saison</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Berger</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Lebosse</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Audoual</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname>
<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Michallet</surname>
<given-names>M</given-names></string-name>. <article-title>Hepatomegaly and fever at the time of neutrophil recovery revealing L-asparaginase toxicity in the treatment of acute lymphoblastic leukemia.</article-title>
<source>Am J Case Rep</source>
<year>2014</year>; <volume>15</volume>: <fpage>13</fpage>-<lpage>7</lpage>.<annotation><p><italic toggle="yes">(52 year old man with ALL developed fever and hepatomegaly by day 25 of chemotherapy and, after 5 injections of asparaginase [bilirubin 7.5 mg/dL, ALT 148 U/L, Alk P 148 U/L], rising for 2 weeks and then returning to normal within 2 months, biopsy showing marked steatosis and mild necrosis).</italic></p></annotation><pub-id pub-id-type="pmid">24454976</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.douer.2014.905">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Douer</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Aldoss</surname>
<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Lunning</surname>
<given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Burke</surname>
<given-names>PW</given-names></string-name>, <string-name name-style="western"><surname>Ramezani</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mark</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Vrona</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal>
<article-title>Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.</article-title>
<source>J Clin Oncol</source>
<year>2014</year>; <volume>32</volume>: <fpage>905</fpage>-<lpage>11</lpage>.<annotation><p><italic toggle="yes">(Among 51 adults with ALL treated with 192 doses of intravenous pegaspargase, ALT or AST elevations occurred in all patients [above 5 times ULN in 63%], and bilirubin in 26 patients [above 3 times ULN in 31%], but all resolved spontaneously [within 6-83 days], although therapy was delayed in 10 patients for high bilirubin and 11 for ALT or AST elevations).</italic></p></annotation><pub-id pub-id-type="pmid">24516026</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.hern_ndez.2014.231">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hern&#x000e1;ndez</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bessone</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>S&#x000e1;nchez</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>di Pace</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Brahm</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zapata</surname>
<given-names>R, A</given-names></string-name>
<string-name name-style="western"><surname>Chirino</surname>
<given-names>R</given-names></string-name>, <etal>et al.</etal>
<article-title>Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports.</article-title>
<source>Ann Hepatol</source>
<year>2014</year>; <volume>13</volume>: <fpage>231</fpage>-<lpage>9</lpage>.<annotation><p><italic toggle="yes">(Among 176 reports of drug induced liver injury from Latin America published between 1996 and 2012, none were attributed to asparaginase or pegaspargase).</italic></p></annotation><pub-id pub-id-type="pmid">24552865</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.chalasani.2015.1340">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chalasani</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bonkovsky</surname>
<given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Fontana</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname>
<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Stolz</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Talwalkar</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Reddy</surname>
<given-names>KR</given-names></string-name>, <etal>et al.</etal>; <collab>United States Drug Induced Liver Injury Network</collab>. <article-title>Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study.</article-title>
<source>Gastroenterology</source>
<year>2015</year>; <volume>148</volume>: <fpage>1340</fpage>-<lpage>52.e7</lpage>.<annotation><p><italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 49 cases [5%] were attributed to antineoplastic agents including 2 to asparaginase and 2 to pegaspargase, all 4 of which were jaundiced, but none were fatal).</italic></p></annotation><pub-id pub-id-type="pmid">25754159</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.horvat.2016.17">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Horvat</surname>
<given-names>TZ</given-names></string-name>, <string-name name-style="western"><surname>Pecoraro</surname>
<given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Daley</surname>
<given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Buie</surname>
<given-names>LW</given-names></string-name>, <string-name name-style="western"><surname>King</surname>
<given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Rampal</surname>
<given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Tallman</surname>
<given-names>MS</given-names></string-name>, <etal>et al.</etal>
<article-title>The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.</article-title>
<source>Leuk Res</source>
<year>2016</year>; <volume>50</volume>: <fpage>17</fpage>-<lpage>20</lpage>.<annotation><p><italic toggle="yes">(Ten adults with ALL with hypersensitivity or intolerance of pegaspargase were able to tolerate Erwinia asparaginase without hypersensitivity reactions and with only mild-to-moderate hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">27631159</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.g_pel.2016.1899">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>G&#x000f6;pel</surname>
<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Schnetzke</surname>
<given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Hochhaus</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Scholl</surname>
<given-names>S</given-names></string-name>. <article-title>Functional acute liver failure after treatment with pegylated asparaginase in a patient with acute lymphoblastic leukemia: potential impact of plasmapheresis.</article-title>
<source>Ann Hematol</source>
<year>2016</year>; <volume>95</volume>: <fpage>1899</fpage>-<lpage>901</lpage>.<annotation><p><italic toggle="yes">(44 year old man with ALL developed liver failure 3 days after receiving pegaspargase [bilirubin rising to ~29 mg/dL, ALTto 2.5 times ULN, GGT to 16 times ULN], recovering over 3 week period following plasmapheresis).</italic></p></annotation><pub-id pub-id-type="pmid">27488287</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.alshiekhnasany.2016.208">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Alshiekh-Nasany</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Douer</surname>
<given-names>D.</given-names></string-name>
<article-title>L-Carnitine for treatment of pegasparaginase-induced hepatotoxicity.</article-title>
<source>Acta Haematol</source>
<year>2016</year>; <volume>135</volume>: <fpage>208</fpage>-<lpage>10</lpage>.<annotation><p><italic toggle="yes">(56 year old man with ALL developed jaundice after a single infusion of pegaspargase [peak bilirubin 26.6 mg/dL, ALT ~230 U/L, Alk P not given], resolving after a 6 day course of L-carnitine).</italic></p></annotation><pub-id pub-id-type="pmid">26841296</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.hijiya.2016.748">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hijiya</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>van der Sluis</surname>
<given-names>IM</given-names></string-name>. <article-title>Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.</article-title>
<source>Leuk Lymphoma</source>
<year>2016</year>; <volume>57</volume>: <fpage>748</fpage>-<lpage>57</lpage>.<annotation><p><italic toggle="yes">(Review of the mechanism of action of asparaginase and its toxicity in children).</italic></p></annotation><pub-id pub-id-type="pmid">26457414</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.toksvang.2017.e26519">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Toksvang</surname>
<given-names>LN</given-names></string-name>, <string-name name-style="western"><surname>De Pietri</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nielsen</surname>
<given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Nersting</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Albertsen</surname>
<given-names>BK</given-names></string-name>, <string-name name-style="western"><surname>Wehner</surname>
<given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Rosth&#x000f8;j</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal>
<article-title>Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.</article-title>
<source>Pediatr Blood Cancer</source>
<year>2017</year>; <volume>64</volume>. <elocation-id>e26519</elocation-id>.<annotation><p><italic toggle="yes">(Among 130 children with ALL receiving a complex chemotherapy regimen that included 8-15 biweekly pegaspargase infusions, 29 developed liver injury diagnosed as sinusoidal obstruction syndrome [SOS] by clinical criteria alone, possibly due to asparaginase effects on mercaptopurine metabolism, but all children recovered).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.liu.2017.131">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Liu</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Fernandez</surname>
<given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname>
<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Panetta</surname>
<given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Kornegay</surname>
<given-names>N</given-names></string-name>, <etal>et al.</etal>
<article-title>Genome-wide study links PNPLA3 variant with elevated hepatic transaminase after acute lymphoblastic leukemia therapy.</article-title>
<source>Clin Pharmacol Ther</source>
<year>2017</year>; <volume>102</volume>: <fpage>131</fpage>-<lpage>40</lpage>.<annotation><p><italic toggle="yes">(Testing of two cohorts of patients receiving asparaginase found associations of posttreatment ALT levels and the PNPLA3 variant that has been linked to ALT elevations in the general population and with alcoholic and nonalcoholic fatty liver disease).</italic></p></annotation><pub-id pub-id-type="pmid">28090653</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF._zdemir.2017.69">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>&#x000d6;zdemir</surname>
<given-names>ZC</given-names></string-name>, <string-name name-style="western"><surname>Turhan</surname>
<given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Eren</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bor</surname>
<given-names>&#x000d6;</given-names></string-name>. <article-title>Is N-acetylcysteine infusion an effective treatment option in L-asparaginase associated hepatotoxicity?</article-title>
<source>Blood Res</source>
<year>2017</year>; <volume>52</volume>: <fpage>69</fpage>-<lpage>71</lpage>.<annotation><p><italic toggle="yes">(2 year old with ALL developed liver test abnormalities after a fifth infusion of an E. coli derived asparaginase [bilirubin 7 mg/dL, ALT 501 U/L, Alk P 246 U/L, GGT 1297 U/L], with recovery after 6 days of N-acetylcysteine infusions and minimal hepatotoxicity with later chemotherapy using Erwinia asparaginase).</italic></p></annotation><pub-id pub-id-type="pmid">28401107</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.blackman.2018.393">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Blackman</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Boutin</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shimanovsky</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname>
<given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Forcello</surname>
<given-names>N</given-names></string-name>. <article-title>Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature.</article-title>
<source>J Oncol Pharm Pract</source>
<year>2018</year>; <volume>24</volume>: <fpage>393</fpage>-<lpage>7</lpage>.<annotation><p><italic toggle="yes">(36 year old woman with ALL developed jaundice 4 days after a second dose of pegaspargase [days 4 and 17 of therapy] [bilirubin 11.5 mg/dL, ALT 2493 U/L, Alk P 270 U/L, INR 1.0], improving rapidly with L-carnitine [50 mg/k/day for 8 days] and vitamin B therapy and tolerating a reduced dose of pegaspargase, and resumption of chemotherapy with recurrence of liver injury 6 weeks later).</italic></p></annotation><pub-id pub-id-type="pmid">28523950</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.burke.2018.49">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Burke</surname>
<given-names>PW</given-names></string-name>, <string-name name-style="western"><surname>Aldoss</surname>
<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Lunning</surname>
<given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Devlin</surname>
<given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Tallman</surname>
<given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Pullarkat</surname>
<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Mohrbacher</surname>
<given-names>AM</given-names></string-name>, <etal>et al.</etal>
<article-title>Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses.</article-title>
<source>Leuk Res.</source>
<year>2018</year>;<volume>66</volume>:<fpage>49</fpage>-<lpage>56</lpage>.<annotation><p><italic toggle="yes">(Among 51 adults with ALL treated with pegaspargase, 16 developed &#x0201c;high grade&#x0201d; hyperbilirubinemia and aminotransferase elevations, usually after the first dose, of whom 11 received another course of pegaspargase only 7 of whom had recurrence and none of whom died of hepatic failure).</italic></p></annotation><pub-id pub-id-type="pmid">29407583</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.schulte.2018.2360">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Schulte</surname>
<given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Madiwale</surname>
<given-names>MV</given-names></string-name>, <string-name name-style="western"><surname>Flower</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hochberg</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Burke</surname>
<given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>McNeer</surname>
<given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>DuVall</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>
<article-title>Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature.</article-title>
<source>Leuk Lymphoma.</source>
<year>2018</year>;<volume>59</volume>:<fpage>2360</fpage>-<lpage>2368</lpage>.<annotation><p><italic toggle="yes">(Among 6 children and young adults with ALL who developed liver injury with jaundice after chemotherapy with pegaspargase who were then treated with levocarnitine, the liver injury resolved in 5 but progressed to end-stage liver disease, pancreatitis and death in one).</italic></p></annotation><pub-id pub-id-type="pmid">29431566</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.arora.2019.e00194">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Arora</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Klair</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bellizzi</surname>
<given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Tanaka</surname>
<given-names>T</given-names></string-name>. <article-title>L-carnitine and vitamin B complex for peg-L-asparaginase-induced hepatotoxicity.</article-title>
<source>ACG Case Rep J.</source>
<year>2019</year>;<volume>6</volume>:<elocation-id>e00194</elocation-id>.<annotation><p><italic toggle="yes">(A 58 year old woman with ALL developed evidence of liver injury 12 days after starting chemotherapy which included pegaspargase, and she was treated with levocarnitine with subsequent peak laboratory values of bilirubin 12.7 mg/dL, ALT 276 U/L and Alk P 1053 U/L, with ultimate complete resolution after which she tolerated chemotherapy using non-pegylated asparaginase).</italic></p></annotation><pub-id pub-id-type="pmid">31737724</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.kamal.2019.641">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kamal</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Koh</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Samala</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Fontana</surname>
<given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Stolz</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Durazo</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hayashi</surname>
<given-names>PH</given-names></string-name>, <etal>et al.</etal>; <collab>Drug-Induced Liver Injury Network</collab>. <article-title>Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis.</article-title>
<source>Hepatol Int.</source>
<year>2019</year>;<volume>13</volume>:<fpage>641</fpage>-<lpage>648</lpage>.<annotation><p><italic toggle="yes">(Among 1321 cases of confirmed drug induced liver injury enrolled in a U.S. prospective database between 2004 and 2017, 60 were due to cancer chemotherapeutic agents including 8 due to asparaginase [n=1] or pegaspargase [n=7], arising 9-21 days after starting therapy with initial and peak values of bilirubin 4.4 and 17.5 mg/dL, ALT 284 and 595 U/L, Alk P 159 and 785 U/L, all with low serum albumin levels [less than 2.0 g/dL], fatty liver by imaging, and ultimate complete resolution, one patient having similar but slightly milder injury upon re-exposure to pegaspargase).</italic></p></annotation><pub-id pub-id-type="pmid">31392570</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.meunier.2020.597">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Meunier</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Larrey</surname>
<given-names>D.</given-names></string-name>
<article-title>Chemotherapy-associated steatohepatitis.</article-title>
<source>Ann Hepatol.</source>
<year>2020</year>;<volume>19</volume>:<fpage>597</fpage>-<lpage>601</lpage>.<annotation><p><italic toggle="yes">(Review of drug induced liver injury associated with steatosis or steatohepatitis including methotrexate, 5-fluorouracil, irinotecan, tamoxifen, and L-asparaginase which may be due to mitochondrial injury and can lead to chronic steatosis and cell injury).</italic></p></annotation><pub-id pub-id-type="pmid">32061473</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.li.2020.328">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Li</surname>
<given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname>
<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Manning</surname>
<given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Di</surname>
<given-names>XM</given-names></string-name>, <string-name name-style="western"><surname>Przepiorka</surname>
<given-names>D</given-names></string-name>, <etal>et al.</etal>
<article-title>FDA approval summary: calaspargase pegol-mknl for treatment of acute lymphoblastic leukemia in children and young adults.</article-title>
<source>Clin Cancer Res.</source>
<year>2020</year>;<volume>26</volume>:<fpage>328</fpage>-<lpage>331</lpage>.<annotation><p><italic toggle="yes">(Summary of data on pharmacokinetics and safety that led to the FDA approval of calaspargase pegol as therapy of ALL in children and young adults [ages 1 month to 21 years] found that calaspargase and pegaspargase had similar patterns and rates of adverse events including ALT elevations above 5 times ULN in 52% vs 66%).</italic></p></annotation><pub-id pub-id-type="pmid">31444252</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.lew.2020.325">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lew</surname>
<given-names>G.</given-names></string-name>
<article-title>Space for calaspargase? a new asparaginase for acute lymphoblastic leukemia.</article-title>
<source>Clin Cancer Res.</source>
<year>2020</year>;<volume>26</volume>:<fpage>325</fpage>-<lpage>327</lpage>.<annotation><p><italic toggle="yes">(Editorial in response to Li et al [2020] mentions that calaspargase has a longer half-life than standard pegaspargase and can be given every 3 weeks, but side effects and efficacy seem to be the same, and the role of calaspargase remains uncertain in the complicated regimens used to treat ALL in children).</italic></p></annotation><pub-id pub-id-type="pmid">31641006</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.vrooman.2021.3496">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Vrooman</surname>
<given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Blonquist</surname>
<given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Stevenson</surname>
<given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Supko</surname>
<given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Hunt</surname>
<given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Cronholm</surname>
<given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Koch</surname>
<given-names>V</given-names></string-name>, <etal>et al.</etal>
<article-title>Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: results of DFCI 11-001.</article-title>
<source>J Clin Oncol.</source>
<year>2021</year>;<volume>39</volume>:<fpage>3496</fpage>-<lpage>3505</lpage>.<annotation><p><italic toggle="yes">(Among 239 children or young adults [ages 1 month to 21 years] with ALL treated with calaspargase pegol every 3 weeks and pegaspargase every 2 weeks [2,500 IU/m<sup>2</sup>per dose] for 30 weeks, drug levels were similar as were rates of response [complete response in 95% vs 99%] and adverse events including hypersensitivity reactions and pancreatitis; no specific mention of ALT levels or hepatotoxicity].</italic></p></annotation><pub-id pub-id-type="pmid">34228505</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.schulte.2021.7551">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Schulte</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hinson</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Huynh</surname>
<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Breese</surname>
<given-names>EH</given-names></string-name>, <string-name name-style="western"><surname>Pierro</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rotz</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mixon</surname>
<given-names>BA</given-names></string-name>, <etal>et al.</etal>
<article-title>Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia.</article-title>
<source>Cancer Med.</source>
<year>2021</year>;<volume>10</volume>:<fpage>7551</fpage>-<lpage>7560</lpage>.<annotation><p><italic toggle="yes">(Comparison of cohorts of pegaspargase treated patients with ALL who did [n=29] or did not [n=109] receive prophylaxis with levocarnitine in variable doses and routes of administration, demonstrated similar rates of hepatotoxicity with or without prophylaxis [14% vs 16%], although post-hoc adjustment for risk factors suggested a protective effect of levocarnitine).</italic></p></annotation><pub-id pub-id-type="pmid">34528411</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.lee.2021.e16917">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lee</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Leventhal</surname>
<given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Anugwom</surname>
<given-names>CM</given-names></string-name>. <article-title>L-Asparaginase-induced hepatotoxicity treated successfully with L-carnitine and vitamin B infusion.</article-title>
<source>Cureus.</source>
<year>2021</year>;<volume>13</volume>:<elocation-id>e16917</elocation-id>.<annotation><p><italic toggle="yes">(69 year old woman with ALL developed evidence of liver injury and pancreatitis after receiving pegaspargase [bilirubin 2.0 rising to 7.6 mg/dL, ALT 72 to 142 U/L, Alk P 282 to 1170 U/L], with fatty liver by ultrasound and liver biopsy showing steatosis and canalicular cholestasis, with ultimate resolution having received a course of levocarnitine and vitamin B complex).</italic></p></annotation><pub-id pub-id-type="pmid">34513489</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.defina.2022.106963">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Defina</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lazzarotto</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Guolo</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Minetto</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Fracchiolla</surname>
<given-names>NS</given-names></string-name>, <string-name name-style="western"><surname>Giglio</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Forghieri</surname>
<given-names>F</given-names></string-name>, <etal>et al.</etal>
<article-title>Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group.</article-title>
<source>Leuk Res.</source>
<year>2022</year>;<volume>122</volume>:<elocation-id>106963</elocation-id>.<annotation><p><italic toggle="yes">(Among 38 adults with ALL who developed asparaginase induced liver injury [33 with pegaspargase], onset was with the first course in 89% with a median latency of 11 [range 0 to 30] days and all received L-carnitine at a median of 2 [range 0 to 51] days after onset, resolving in a median of 14 [range 5 to 58] days, data that are similar to the literature on untreated asparaginase hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">36155352</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.wu.2022.113000">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wu</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Alqahtani</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lou</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stock</surname>
<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Bhojwani</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Alachkar</surname>
<given-names>H</given-names></string-name>. <article-title>Hispanic ethnicity and the rs4880 variant in SOD2 are associated with elevated liver enzymes and bilirubin levels in children receiving asparaginase-containing chemotherapy for acute lymphoblastic leukemia.</article-title>
<source>Biomed Pharmacother.</source>
<year>2022</year>;<volume>150</volume>:<elocation-id>113000</elocation-id>.<annotation><p><italic toggle="yes">(Among 143 children with ALL treated with asparaginase, hepatoxicity arose in 47% of Hispanic vs 33% of non-Hispanics, the Hispanic children being more likely to be overweight or obese [53% vs 44%] and more likely to have the CC genotype of rs4880 SNP of superoxide dismutase 2 [SOD2: 43% vs 15%]; in multivariate analysis, only Hispanic ethnicity was a significant risk factor for asparaginase hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">35658244</pub-id></mixed-citation>
          </ref>
          <ref id="Asparaginase.REF.vetro.2022.1142">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Vetro</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Duminuco</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gozzo</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Maugeri</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Parisi</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Brancati</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Longo</surname>
<given-names>L</given-names></string-name>, <etal>et al.</etal>
<article-title>Pegylated asparaginase-induced liver injury: a case-based review and data from pharmacovigilance.</article-title>
<source>J Clin Pharmacol.</source>
<year>2022</year>;<volume>62</volume>: <fpage>1142</fpage>-<lpage>1150</lpage>.<annotation><p><italic toggle="yes">(59 year old woman with ALL developed pancreatitis within a week of starting chemotherapy which included pegaspargase and which was followed by jaundice and progressive liver failure, lactic acidosis and death 37 days after starting chemotherapy).</italic></p></annotation><pub-id pub-id-type="pmid">35342960</pub-id></mixed-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Asparaginase.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=Asparaginase+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Asparaginase: from PubMed.gov</ext-link>
</p>
        <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Asparaginase">Trials on Asparaginase: from ClinicalTrials.gov</ext-link>
</p>
        <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=Pegaspargase+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Pegaspargase: from PubMed.gov</ext-link>
</p>
        <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Pegaspargase">Trials on Pegaspargase: from ClinicalTrials.gov</ext-link>
</p>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
